I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas.
Here’s what he had to say:
“I can say that this is an exciting time for regenerative medicine. The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for a long list of diseases.”
The day after hearing the news, I myself feel a bit more optimistic that Astellas will continue this important work and help patients with vision impairment as well as other diseases.